Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Key facts

Sponsor

Corvus Pharmaceuticals, Inc.

Principal Investigator

Suresh Mahabhashyam, MD, MPH

Corvus Pharmaceuticals, Inc.

Intervention

Soquelitinib(drug)

Enrollment

150 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (27)

• City of Hope National Medical Center, Duarte, California, United States
• University of California, Irvine, Irvine, California, United States
• University of California San Francisco, San Francisco, California, United States
• Yale University, New Haven, Connecticut, United States
• Emory University, Atlanta, Georgia, United States
• University of Iowa, Iowa City, Iowa, United States
• University of Maryland Medical Center, Baltimore, Maryland, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• University of Michigan, Ann Arbor, Michigan, United States
• Washington University in St. Louis, St Louis, Missouri, United States
• Hackensack University Medical Center, Hackensack, New Jersey, United States
• Icahn School of Medicine at Mount Sinai, New York, New York, United States
• North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
• The Ohio State University, Columbus, Ohio, United States
• MD Anderson Cancer Center, Houston, Texas, United States
• +12 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06494371
  A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
  Ruijin Hospital
• RECRUITINGPHASE1, PHASE2NCT06137144
  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
  AstraZeneca
• ACTIVE NOT RECRUITINGPHASE1NCT04526834
  Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
  Tessa Therapeutics
• ACTIVE NOT RECRUITINGPHASE3NCT04881838
  CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
  Children's Cancer Group, China
• ACTIVE NOT RECRUITINGPHASE2NCT02978625
  Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
  National Cancer Institute (NCI)
• RECRUITINGNCT04220970
  Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
  The Lymphoma Academic Research Organisation

See all trials for Anaplastic large cell lymphoma →